Ruben A. Mesa, MD:This is a 39-year-old gentleman with polycythemia vera. Specifically, he presented with significant erythrocytosis without leukocytosis or thrombocytosis. He had a bone marrow aspirate and biopsy done, which showed morphologic features consistent with polycythemia vera, as well as the presence of theJAK2mutation. He had a normal karyotype. He did not have a significant increase in fibrosis; he just had 1+ fibrosis. So, he met the WHO 2016 criteria for a diagnosis of polycythemia vera. Now, in managing a patient like this, we have to first assess their risk. And the risk factors for polycythemia vera that we consider are an age greater than 60 and prior thrombotic events or hemorrhagic events, which this individual has not had. However, this individual does have significant cardiovascular risk factorssome hypertension, some diabetes—and those are additional factors. So, in my practice, I would consider this individual as having an intermediate-risk polycythemia vera.
The goals for managing a patient like this are several-fold. They are really aimed at trying to prevent thrombosis or bleeding, and they include, certainly, trying to manage his cardiovascular risk factors. So, individuals are managed on a basis of phlebotomy to control the hematocrit. Ideally, in 2017, we know our targets would be a hematocrit of less than 45%, as well as the use of low-dose aspirin: 81 mg in the United States but 100 mg or less, given the different formulations, around the world. We’ll be monitoring the patient to be sure that we’re keeping up with their phlebotomyit needs to keep the hematocrit under 45%—as well as making certain they’re not having vascular events, they’re not developing splenomegaly, and they’re not developing symptoms or other difficult disease features.
This patient began on phlebotomies and, after 3 months, is having difficulties with phlebotomy, having a variety of side effects: fatigue, dizziness, and other problematic issues. So, the individual has begun on hydroxyurea as a cytoreductive therapy. The need for phlebotomies continues, and the dose of hydroxyurea is increased further from 1000 mg to 1500 mg a day.
Transcript edited for clarity.
January 2015
April 2015
July 2015
October 2015
January 2016
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More